Reduction in the risk of human breast cancer by selective cyclooxygenase-2 (COX-2) inhibitors
2006

Reducing Breast Cancer Risk with COX-2 Inhibitors

Sample size: 972 publication 10 minutes Evidence: high

Author Information

Author(s): Harris Randall E, Beebe-Donk Joanne, Alshafie Galal A

Primary Institution: The Ohio State University College of Medicine and Public Health

Hypothesis

Do selective COX-2 inhibitors reduce the risk of breast cancer?

Conclusion

Selective COX-2 inhibitors significantly reduce the risk of breast cancer by 71%.

Supporting Evidence

  • Selective COX-2 inhibitors showed a significant risk reduction for breast cancer.
  • Regular aspirin and ibuprofen also reduced breast cancer risk.
  • Acetaminophen did not affect breast cancer risk.

Takeaway

Taking certain medications called COX-2 inhibitors can help lower the chances of getting breast cancer.

Methodology

A case-control study comparing 323 breast cancer patients with 649 cancer-free controls.

Potential Biases

Potential bias due to the reliance on self-reported medication use.

Limitations

The study is limited by the short exposure window to COX-2 inhibitors and the recall of one of the drugs.

Participant Demographics

Participants included 323 breast cancer patients and 649 matched controls based on age, race, and county.

Statistical Information

P-Value

0.29

Confidence Interval

0.14–0.59

Statistical Significance

p<0.05

Digital Object Identifier (DOI)

10.1186/1471-2407-6-27

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication